Last $11.13 USD
Change Today -0.14 / -1.24%
Volume 504.8K
VNDA On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

vanda pharmaceuticals inc (VNDA) Snapshot

Open
$11.22
Previous Close
$11.27
Day High
$11.65
Day Low
$11.07
52 Week High
03/24/14 - $19.25
52 Week Low
10/13/14 - $8.34
Market Cap
441.3M
Average Volume 10 Days
602.7K
EPS TTM
$-1.70
Shares Outstanding
39.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VANDA PHARMACEUTICALS INC (VNDA)

vanda pharmaceuticals inc (VNDA) Related Businessweek News

No Related Businessweek News Found

vanda pharmaceuticals inc (VNDA) Details

Vanda Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development and commercialization of pharmaceutical products. Its product portfolio includes HETLIOZ, a product for the treatment of Non-24-Hour Sleep-Wake Disorder; Fanapt, a product for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor antagonist. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

60 Employees
Last Reported Date: 10/27/14
Founded in 2002

vanda pharmaceuticals inc (VNDA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $515.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $279.8K
Compensation as of Fiscal Year 2013.

vanda pharmaceuticals inc (VNDA) Key Developments

Vanda Pharmaceuticals, Inc. - Special Call

To discuss settlement agreement with Novartis AG, commercialization plans for Fanapt, the AQW051 program and other corporate activities

Vanda Pharmaceuticals, Inc. Reaches Settlement Agreement with Novartis AG

Vanda Pharmaceuticals Inc. announced that it has reached a settlement agreement with Novartis AG related to the ongoing Fanapt license arbitration proceedings. The parties have agreed to dismiss the ongoing Fanapt arbitration and to release each other from any related claims. As a part of the settlement agreement, Novartis will transfer all US and Canadian rights in the Fanapt franchise to Vanda, make a $25 million equity investment in Vanda at a price per share equal to $13.82 and grant to Vanda an exclusive worldwide license to AQW051, a phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Vanda Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Vanda Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $11.13 USD -0.14

VNDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,743 GBp -18.50
Eli Lilly & Co $72.00 USD -0.11
Pfizer Inc $31.25 USD -0.58
Sanofi €82.00 EUR -0.26
Sumitomo Dainippon Pharma Co Ltd ¥1,244 JPY +36.00
View Industry Companies
 

Industry Analysis

VNDA

Industry Average

Valuation VNDA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.7x
Price/Book 355.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit www.vandapharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.